Inflexion in 2.8x pharma exit

The UK-based firm has agreed to sell Phlexglobal to Bridgepoint Development Capital for £42m

14 July 2014•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.